Blood Pressure Response Following Radiofrequency Renal Denervation in a Large Commercial U.S. Cohort

© 2025 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Cath Lab Digest or HMP Global, their employees, and affiliates. 

Jeremy S. Bock, MD, FACC, FSCAI, is the Medical Director for Cardiology, Virginia Hospital Center Health in Arlington, Virginia.

An interventional cardiologist and endovascular specialist, Dr. Bock discusses his study looking at blood pressure response following radiofrequency renal denervation in the largest real-world U.S. cohort, including older patients, recently presented at the CRT meeting in Washington, D.C. 

The data include a study of the largest cohort of commercially treated, uncontrolled hypertensive patients at a single center (six months after approval) who underwent radiofrequency (RF) renal denervation (RDN) with Symplicity Spyral (Medtronic). The analysis was conducted to assess blood pressure changes, specifically office systolic blood pressure, at six- and twelve-months post-procedure. Safety outcomes were also evaluated. 

Dr. Jeremy Bock can be contacted at jbock@vhchealth.org

Note: See some of the slides from Dr. Bock's presentation below the video.